What did @dragnesusoro actually say?
Dr. Agnes Usoro made three core claims: semaglutide and tirzepatide are both GLP-1 injections, the difference between them is "just a small change in their molecular structure," and "theoretically, you can use them interchangeably." She also compared them to ibuprofen and naproxen, suggesting they essentially do the same thing. She works from a Houston medical spa and framed this as a complete primer on both drugs.
The video is mostly well-intentioned and avoids the worst GLP-1 hype on TikTok. But a few of those claims are either incomplete or flatly wrong, and one of them, the interchangeability framing, could genuinely mislead someone managing their weight or blood sugar on these medications.
Does the science back this up?
Partially. The GLP-1 agonist classification is correct for both drugs, but tirzepatide is not purely a GLP-1 agonist, and that distinction matters clinically. The Advil-versus-Aleve comparison is a creative teaching tool that oversimplifies real pharmacological differences.
Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 receptor agonist. That second mechanism, activating the glucose-dependent insulinotropic polypeptide receptor, is not a trivial molecular footnote. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found tirzepatide at its highest dose produced roughly 22.5% body weight reduction. The STEP 1 trial of semaglutide (Wilding et al., 2021, NEJM) showed approximately 14.9% reduction. That is not a rounding error. The caption on this very video acknowledges "slightly more weight loss with tirzepatide," but the transcript undersells that gap significantly by calling them essentially the same.
The interchangeability claim is where the video gets into real trouble. Switching patients between these drugs is done clinically, but it requires dose recalibration, monitoring, and medical judgment. Framing it as theoretically plug-and-play is irresponsible shorthand for a general audience.
What did they get wrong (or right)?
Let's separate the good from the bad.
What she got right
- Both drugs do activate GLP-1 receptors. That is accurate.
- Plateau-driven switching between GLP-1 agents is a real clinical practice, supported by case series and prescriber experience, though large randomized trials comparing head-to-head switching protocols are still limited.
- Pairing these medications with protein-rich diets and resistance training is well-supported. A 2023 study (Wilding et al., Diabetes, Obesity and Metabolism) noted that lean mass preservation during GLP-1 therapy improves with exercise intervention.
What she got wrong
- Tirzepatide is not just a slightly different version of semaglutide. It is a dual-agonist drug with a meaningfully different mechanism. The Advil-Aleve comparison breaks down here because both of those are NSAIDs with the same mechanism class. Tirzepatide adds an entirely separate receptor pathway.
- "Theoretically, you can use them interchangeably" is the kind of phrase that patients repeat to their pharmacists to justify skipping a provider conversation. These drugs have different titration schedules, different side effect profiles, and different insurance coverage pathways. They are not swappable without clinical oversight.
What should you actually know?
If you are considering either drug, the pharmacological difference between semaglutide and tirzepatide is not just a molecular technicality. It has real-world effects on how much weight you may lose, how your blood sugar responds, and what side effects you might experience.
The GIP receptor activation in tirzepatide appears to improve insulin sensitivity and may reduce nausea compared to semaglutide at comparable doses, according to mechanistic data reviewed by Farzam and colleagues (2023, StatPearls). That is not the same drug doing the same thing through a slightly different door.
Switching between these medications when you plateau is a legitimate clinical strategy, but it is not something to self-direct based on a TikTok video. Dose conversion between agents is not standardized, and starting tirzepatide after semaglutide without proper titration can increase GI side effects or, in people with diabetes, affect glycemic control in unpredictable ways.
Both drugs are prescription-only for a reason. If you are curious whether one might work better for you than the other, that is a question for a prescribing provider who knows your full history, not a comment section.